The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab
@article{HBSN108292,
author = {Sabine Lieb and Sebastian Ebel and Daniel Seehofer and Thomas Berg and Florian van Bömmel},
title = {The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab},
journal = {HepatoBiliary Surgery and Nutrition},
volume = {12},
number = {1},
year = {2023},
keywords = {},
abstract = {},
issn = {2304-389X}, url = {https://hbsn.amegroups.org/article/view/108292}
}